Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors

Immune checkpoint inhibitors (ICIs) can block distinct receptors on T cells or tumor cells thus preventing T cell inactivation and tumor immune escape. While the clinical response to treatment with ICIs in cancer patients is impressive, this therapy is often associated with a number of immune-relate...

Descripción completa

Detalles Bibliográficos
Autores principales: Reul, Johanna, Frisch, Janina, Engeland, Christine E., Thalheimer, Frederic B., Hartmann, Jessica, Ungerechts, Guy, Buchholz, Christian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382738/
https://www.ncbi.nlm.nih.gov/pubmed/30838171
http://dx.doi.org/10.3389/fonc.2019.00052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382738/
https://www.ncbi.nlm.nih.gov/pubmed/30838171
http://dx.doi.org/10.3389/fonc.2019.00052

Ejemplares similares